161 Startups
  • Sector
  • Participated in
  • Year of participation

Sencilia

  • 2023
  • Medical Device
  • Venture Challenge
Sencilia has developed a first-of-its-kind flow sensing device to reduce medication errors due to flow instabilities in intravenous infusions in neonates.

SeraNovo

  • 2018
  • Enabling Technology
  • Venture Challenge
SeraNovo’s proprietary formulation platform radically increases bioavailability and allows products to reach the market significantly quicker, at a lower cost.

ShanX Medtech

  • 2020
  • Diagnostics
  • Venture Challenge
Providing a reliable UTI diagnosis and simultaneously indicating the optimal antibiotic prescription in under 4 hours

Sherwood Pharmacuticals

  • 2025
  • Venture Challenge
Sherwood Pharmaceuticals develops the first targeted therapy for Cri du Chat syndrome, repurposing safe small molecules to improve outcomes for patients with this rare genetic disorder.

SimpleXable

  • 2022
  • Enabling Technology
  • Venture Challenge
Simplexable provides three-dimensional human scar models that are suitable for high content screening of compounds, targeting key events of hypertrophic scar formation.

Sirius Medical

  • 2015
  • Medical Device
  • Venture Challenge
The next generation of accurate and hassle-free tumor localization for breast cancer.

SLAM Orthopedic

  • 2020
  • Medical Device
  • Venture Challenge
SLAM Ortho has developed an automated, accurate and fast bore depth measurement system for use in orthopaedic trauma procedures for fractures in extremities

Sniper Therapeutics

  • 2024
  • Therapeutics
  • Venture Challenge
Sniper Therapeutics enhances T-cell therapies for solid tumors by selecting and utilizing only tumor-killing T cells, resulting in more effective treatments.

Spatium Medical

  • 2023
  • Medical Device
  • Venture Challenge
Spatium Medical introduces the world’s first medical insufflator that ensures stable workspace at lowest insufflation and ventilation pressure with three patented technologies addressing three unmet needs.

StemXBio

  • 2024
  • Enabling Technology
  • Venture Challenge
StemX Bio's revolutionary human in vitro 3D pancreatic model will completely transform the area of diabetes drug discovery. This innovative approach directly addresses the critical unmet need within the diabetes research community for more accurate and physiologically relevant in vitro models.